Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 22, 2026, 3:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 2,050 matching trials from the live ClinicalTrials.gov search.
Conditions
Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer
Interventions
Luveltamab tazevibulin, Pegfilgrastim, Gemcitabine, Paclitaxel, Pegylated liposomal doxorubicin, Topotecan
Drug
Lead sponsor
Sutro Biopharma, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
37
States / cities
Tucson, Arizona • Daly City, California • San Diego, California + 33 more
Conditions
Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
temozolomide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
New York, New York
Conditions
Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer, Lung Squamous Cell Carcinoma
Interventions
Torvutatug samrotecan, Saruparib, Bevacizumab, Carboplatin, Palacaparib, Pembrolizumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
622 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
13
States / cities
Duarte, California • Irvine, California • La Jolla, California + 9 more
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
plevitrexed, topotecan hydrochloride
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Wilmington, Delaware
Conditions
Ovarian Cancer, High Grade Ovarian Serous
Interventions
PET/MRI, Contrast enhanced CT
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
New York, New York
Conditions
Polycystic Ovary Syndrome
Interventions
Cinnamon Extract, Placebo
Drug · Dietary Supplement
Lead sponsor
Rogerio A. Lobo
Other
Eligibility
18 Years to 38 Years · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
New York, New York
Conditions
Solid Tumors
Interventions
RMC-5552
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
8
States / cities
Irvine, California • Sacramento, California • San Francisco, California + 5 more
Conditions
FSH Hypersecretion, Endocrine System Diseases, Infertility
Interventions
CPA
Other
Lead sponsor
Clear Passage Therapies, Inc
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Ovarian Neoplasms
Interventions
AZD2281, Liposomal Doxorubicin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • Boca Raton, Florida + 3 more
Conditions
Malignancy, Cancer, Non Small Cell Lung Cancer, Small Cell Lung Cancer, Testicular Cancer, Thymoma, Ovarian Cancer, Osteosarcoma
Interventions
palifosfamide-tris
Drug
Lead sponsor
Alaunos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Indianapolis, Indiana • Lafayette, Indiana • Muncie, Indiana + 1 more
Completed Phase 2 Interventional Results available

Ovarian Cancer Vaccine for Patients in Remission

NCT01068509
Conditions
Epithelial Ovarian Cancer
Interventions
Cvac
Biological
Lead sponsor
Prima BioMed Ltd
Industry
Eligibility
18 Years and older · Female only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
13
States / cities
Greenbrae, California • La Jolla, California • Palo Alto, California + 10 more
Conditions
Estrogen Receptor Negative, HER2/Neu Negative, Male Breast Carcinoma, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage IV Breast Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma
Interventions
Laboratory Biomarker Analysis, Pegylated Liposomal Doxorubicin Hydrochloride, Pharmacological Study, Veliparib
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
6
States / cities
New York, New York • The Bronx, New York
Conditions
Endometrial Clear Cell Adenocarcinoma, Ovarian Clear Cell Cystadenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Cancer
Interventions
Dasatinib, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
227
States / cities
Anchorage, Alaska • Auburn, California • Berkeley, California + 154 more
Conditions
Cancer, Physical Activity, Cancer Survivorship, Mental Health, Obesity
Interventions
AYA Connect intervention, Positive Psychology (PP) intervention, Positive Psychology Plus (PP+) intervention
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 39 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Completed Phase 1Phase 2 Interventional Results available

A Study LY2228820 for Recurrent Ovarian Cancer

NCT01663857
Conditions
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions
LY2228820, Carboplatin, Placebo, Gemcitabine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
19
States / cities
Phoenix, Arizona • Tucson, Arizona • Sarasota, Florida + 15 more
Conditions
Ovarian Cancer
Interventions
physiologic testing, study of high risk factors
Other · Procedure
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
30 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer, Gastric Cancer, Esophageal Cancer, Hepatocellular Carcinoma, Renal Cell Carcinoma, Breast Cancer, Sarcoma, Bladder Cancer, Lung Cancer, Prostate Cancer, Cervical Cancers, Head and Neck Cancers, Adrenal Gland Tumors
Interventions
IDOV-Immune (oncolytic vaccinia virus)
Biological
Lead sponsor
ViroMissile, Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
St Louis, Missouri • Houston, Texas • San Antonio, Texas
Conditions
Estrogen Receptor Positive, Postmenopausal, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma
Interventions
Laboratory Biomarker Analysis, Letrozole, Ribociclib
Other · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Conditions
Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma
Interventions
Bevacizumab, Abraxane
Drug
Lead sponsor
Accelerated Community Oncology Research Network
Other
Eligibility
18 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
11
States / cities
Little Rock, Arkansas • La Verne, California • Athens, Georgia + 8 more
Conditions
Ovarian Cancer, Recurrent Solid Tumors
Interventions
ZEN003694, Niraparib
Drug
Lead sponsor
Haider Mahdi
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
High Grade Serous Ovarian, Ovarian Adenocarcinoma, Ovarian Cancer, Serous Adenocarcinoma of Ovary, Ovarian Cancer (OvCa)
Interventions
Exercise, Usual Care
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Completed Phase 4 Interventional Accepts healthy volunteers

The Use of GnRH Agonist Trigger in the Prevention of OHSS

NCT00349258
Conditions
Ovarian Hyperstimulation Syndrome
Interventions
Leuprolide acetate
Drug
Lead sponsor
University of Connecticut
Other
Eligibility
20 Years to 39 Years · Female only
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Farmington, Connecticut
Conditions
Metastatic Solid Tumors, Stage 4 Cancer
Interventions
The Sarah Nanotechnology System - intended to deliver thermal energy to malignant cells for the purpose of thermal destruction of these cells in patients with advanced metastatic solid tumors.
Device
Lead sponsor
New Phase Ltd.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Lung Cancer, Ovarian Cancer, Uterine Cancer, Colorectal Cancer, Stomach Cancer, Esophageal Cancer, Pancreatic Cancer, Melanoma, Breast Cancer, Head and Neck Cancer, Soft Tissue Sarcoma, Rhabdomyosarcoma, Prostate Cancer
Interventions
OmniSeq Test
Diagnostic Test
Lead sponsor
Labcorp Corporation of America Holdings, Inc
Industry
Eligibility
18 Years and older
Enrollment
1,429 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
8
States / cities
Fort Payne, Alabama • Orange City, Florida • Stuart, Florida + 5 more